Chemotherapy-Induced Peripheral Neuropathy (CIPN)

Preclinical models to study nerve damage and pain from chemotherapy.

SPEAK WITH A SCIENTIST

mdbiosciences-neurology-leading-preclinical-CRO-1

Preclinical Efficacy Models of Chemotherapy-Induced Pain

Neurotoxicity and peripheral neuropathy are common side effects of chemotherapy, often limiting the dose needed for optimal anti-tumor effects. MD Biosciences offers preclinical models of chemotherapy-induced neuropathic pain, providing reliable tools to evaluate novel interventions and better understand mechanisms of nerve damage and pain associated with chemotherapy.

REQUEST A STUDY QUOTE
Scientific Data

Von Frey in the CIPN Rodent Model

Withdrawal force in rats treated with a chemotherapeutic agent falls from baseline by day 14 and remains reduced through day 28, confirming mechanical allodynia. Males stay at the reduced level for the length of the study, while females show a partial recovery from day 21, a difference that supports including both sexes in CIPN efficacy studies.

VIEW DATASHEET

von frey in CIPN

Assessments

MD Biosciences offers comprehensive in vivo measures and endpoint assessments, delivering robust data packages to support critical research decisions in the evolving landscape of drug development and biomedical research.

behavior

Behavior 

Conduct extensive pain, sensory, motor, and cognitive behavioral testing.

biomarker

Biomarkers

Explore inflammatory and pain biomarkers in disease-specific tissues.

histology

Histology

Characterize tissue and cellular changes in disease, pain, and neurodegeneration.

Explore our Resources

Plan a CIPN study

Request a quote for a CIPN study, or speak with a scientist about the chemotherapeutic agent and dosing schedule.

REQUEST A STUDY QUOTE
SPEAK WITH A SCIENTIST